We haven't seen as many of those break through deals the past two weeks, and next week is going to be more of the same. But there's a lot more strength in the biotech market than the last two week's run on the sector would indicate.
This next week will be very, very quiet. Not only are there very few deals, but these are deals that wouldn't do well in a strong market.
This is the early salvo of the next generation of utility firms. It's a pretty big deal but should still have a pretty solid debut.